Medicare AdvantageCoverageMedium impact
MA08.058h, Blinatumomab (Blincyto®)
Independence Blue Cross·Oncology, Hematology, Pediatrics +1 more·Pharmacy
Effective date
Oct 20, 2025
We identified it
Jun 19, 2026
Summary
Independence Blue Cross updated MA08.058h to align blinatumomab (Blincyto) coverage criteria with current NCCN recommendations for acute lymphoblastic leukemia (ALL). The policy now reorganizes coverage by Philadelphia Chromosome status first, then by MRD status, and adds new treatment regimens for ALL with additional mutations. ICD-10 diagnosis codes were removed from the policy; providers must now report the most appropriate code based on the medically necessary criteria listed.
Action Required
By October 20, 2025: Billing team must update prior authorization workflows and clinical criteria in billing/authorization systems to reflect the new Philadelphia Chromosome-first categorization followed by MRD status for blinatumomab coverage decisions. Providers and authorizers should review the updated NCCN-aligned indications (Philadelphia Chromosome-positive B-ALL, Philadelphia Chromosome-negative B-ALL, pediatric, and infant ALL categories) to ensure correct medical necessity documentation. Clinical staff must document appropriate ICD-10 diagnosis codes supporting medically necessary criteria, as the policy no longer includes a reference list of codes. Update encounter templates and prior auth request forms to capture Philadelphia Chromosome status and MRD results where applicable. Flag claims for J9039 that lack sufficient clinical documentation of ALL subtype and disease status for potential denial.